ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriatic arthritis and registry"

  • Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting

    Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J. Mease1, Mei Liu2, Sabrina Rebello3, Winnie Hua2, Robert R. McLean2, Peter Hur4 and Alexis Ogdie5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Southborough, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
  • Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Alexis Ogdie1, Mei Liu2, Sabrina Rebello3, Meghan Glynn2, Peter Hur4 and Philip J. Mease5, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Southborough, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, 5Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…
  • Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting

    Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Alexis Ogdie1, Mei Liu2, Meghan Glynn2, Kelechi Emeanuru2, Leslie R Harrold3, Sven Richter4, Benoit Guerette4 and Philip J. Mease5, 1University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Celgene Corporation, Summit, NJ, 5Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
  • Abstract Number: 2592 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry

    Herman F Mann1, Jakub Zavada2, Lucie Nekvindová3, Zlatuse Kristkova3, Pavel Horák4, Jiri Vencovsky1 and Karel Pavelka2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, 4IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic

    Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A…
  • Abstract Number: 2620 • 2018 ACR/ARHP Annual Meeting

    The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort

    Umut Kalyoncu1, Abdulsamet Erden1, Gezmis Kimyon2, Timucin Kasifoglu3, Atalay Dogru4, Ozun Bayndır5, Ediz Dalkiliç6, Cem Ozisler1, Ayse Balkarli1, Gozde Cetin7, Rıdvan Mercan8, Orhan Kucuksahin1, Ahmet Omma1, Serpil Ergullu Esmen9, Levent Kilic1, Dilek Solmaz10, Muhammet Cinar1, Seval Pehlevan11, Sema Yilmaz9, Tuncay Duruoz11, Sibel Bakirci5 and Sibel Zehra Aydın12, 1PsART study group, Ankara, Turkey, 2PsART study group, Hatay, Turkey, 3PsART study group, Eskişehir, Turkey, 4PsART study group, Isparta, Turkey, 5PsART study group, Izmir, Turkey, 6PsART study group, Bursa, Turkey, 7PsART study group, Kahramanmaras, Turkey, 8PsART study group, Tekirdag, Turkey, 9PsART study group, Konya, Turkey, 10PsART study group, Ottawa, OH, Canada, 11PsART study group, Istanbul, Turkey, 12PsART study group, Ottawa, ON, Canada

    Background/Purpose: There had been a lot of new therapeutic agents for the treatment of Psoriatic Arthritis (PsA) in the last decade. In this study we…
  • Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting

    Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry

    Philip J Mease1, Jacqueline B. Palmer2, Mark Lebwohl3, Chitra Karki4, George W. Reed5, Carol J. Etzel6, Jeffrey D. Greenberg7 and Philip S. Helliwell8, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Corrona, LLC, Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7New York University School of Medicine, New York, NY, 8School of Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
  • Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting

    Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab

    Laura C Coates1, Proton Rahman2, Eliofotisti Psaradellis3, Emmanouil Rampakakis3, Brendan Osborne4, Allen J Lehman5 and Francois Nantel4, 1LIRMM, University of Leeds, Leeds, United Kingdom, 2Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 3JSS Medical Research, Montreal, QC, Canada, 4Medical Affairs, Janssen Inc., Toronto, ON, Canada, 5Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
  • Abstract Number: 612 • 2017 ACR/ARHP Annual Meeting

    Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period

    Regan Arendse1, Anna Jaroszynska2, Derek Haaland3, Pauline Boulos4, Isabelle Fortin5, Raheem Kherani6, Ariel Masetto7, Jonathan Chan8, Eliofotisti Psaradellis9, Melissa Stutz9, Brendan Osborne10, Francois Nantel10 and Allen J Lehman11, 1University of Saskatchewan, Saskatoon, SK, Canada, 2Private practice, Burlington, ON, Canada, 3Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, 4Rheumatology, McMaster University, Hamilton, ON, Canada, 5Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, 6University of British Columbia, Richmond, BC, Canada, 7Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 8Rheumatology, University of British Columbia, Vancouver, BC, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Ustekinumab (UST) is a fully human immunoglobin monoclonal antibody against interleukin-12 (IL-12) and interleukin-23 (IL-23) that has been proven safe and efficacious for the…
  • Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting

    Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Chitra Karki2, Mei Liu2, YouFu Li3, Peter Hur4 and Jeffrey D. Greenberg5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5New York University School of Medicine, New York, NY

    Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
  • Abstract Number: 2520 • 2017 ACR/ARHP Annual Meeting

    Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World

    Michelle Teo1, Derek Haaland2, John Kelsall3, Isabelle Fortin4, Pauline Boulos5, Raman Rai6, Sanjay Dixit7, B Haraoui8, Dalton Sholter9, Eliofotisti Psaradellis10, Emmanouil Rampakakis10, Brendan Osborne11, Francois Nantel11 and Allen J Lehman12, 1Balfour Medical Clinic, Penticton, BC, Canada, 2Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, 3Rheumatology, University of British Columbia, Vancouver, BC, Canada, 4Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, 5Rheumatology, McMaster University, Hamilton, ON, Canada, 6Private Practice, Hamilton, ON, Canada, 7Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, 8Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 9Rheumatology Associates, Edmonton, AB, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs)…
  • Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting

    Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Chitra Karki2, Mei Liu2, Arthur Kavanaugh3, Christopher T. Ritchlin4, Doquyen H. Huynh3, Renganayaki Pandurengan2, Jacqueline B. Palmer5 and Jeffrey D. Greenberg2,6, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of California San Diego, La Jolla, CA, 4Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6New York University School of Medicine, New York, NY

    Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
  • Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting

    Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab

    Dalton Sholter1, Proton Rahman2, Maqbool Sheriff3, Michel Zummer4, Suneil Kapur5, Philip Baer6, Michael Starr7, John Kelsall8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Brendan Osborne11, Karina Maslova12, Cathy Tkaczyk11, Francois Nantel13 and Allen J Lehman12, 1University of Alberta, Edmonton, AB, Canada, 2Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 4Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 5University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, 6Independent Rheumatology Practice, Scarborough, ON, Canada, 7Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, 8Rheumatology, University of British Columbia, Vancouver, BC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 1319 Green belt Dr, Janssen Inc., Toronto, ON, Canada

    Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…
  • Abstract Number: 2721 • 2016 ACR/ARHP Annual Meeting

    Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Jacqueline B. Palmer2, Heather J. Litman3, Chitra Karki3 and Jeffrey D. Greenberg3,4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Corrona, LLC, Southborough, MA, 4New York University School of Medicine, New York, NY

    Background/Purpose: Studies have shown that psoriasis of the skin, scalp and/or nails precedes the appearance of psoriatic arthritis (PsA) by up to 12 years1,2; however,…
  • Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting

    Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

    J. Antonio Avina-Zubieta1, Andrew Chow2, Philip Baer3, John Kelsall4, Proton Rahman5, Jacqueline Stewart6, Boulos Haraoui7, Michel Zummer8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Francois Nantel11, Karina Maslova12, Cathy Tkaczyk13, Brendan Osborne13 and Allen J Lehman12, 1Arthritis Research Canada, Richmond, BC, Canada, 2Credit Valley Rheumatology, Mississauga, ON, Canada, 3Independent Rheumatology Practice, Scarborough, ON, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 6Penticton Regional Hospital, Penticton, BC, Canada, 7University of Montreal, Montreal, QC, Canada, 8Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 1119 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
  • Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting

    Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis

    Louis Bessette1, Proton Rahman2, Denis Choquette3, John Kelsall4, Maqbool Sheriff5, Emmanouil Rampakakis6, Eliofotisti Psaradellis7, Allen J Lehman8, Karina Maslova8, Francois Nantel9,10, Brendan Osborne11 and Cathy Tkaczyk11, 1Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, 2Medicine, Memorial University, St John's, NF, Canada, 3Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 5Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 6JSS Medical Research, St-Laurent, QC, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, 1019 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology